Screening Study for Participants With Malignant Tumors
- Cancer
- Solid Tumors
Recruiting
- Ankara
- Auckland
- Austin
- Beograd
- Blacksburg
- Bogotá
- Bunkyo City
- chang-wat-nonthaburi
- Cheongju-si
- Daegu
- Erzurum
- Fukuoka
- Gwangju
- Himeji
- Hirosaki
- Hong Kong Island
- İstanbul
- Kagoshima
- Kashihara
- Knoxville
- Kobe
- Koto City
- Kragujevac
- Krung Thep Maha Nakhon
- Kumamoto
- Kurashiki
- Kurume
- London
- Longmont
- Manchester
- Matsuyama
- Melbourne
- Memphis
- Minas Gerais
- Nagaizumi
- Nagoya
- New Taipei City
- Niigata
- Okayama
- Osaka
- Osakasayama
- Pittsburgh
- Portland
- Providencia
- Rio Grande do Sul
- Sakai
- Samsun
- San Antonio
- San Diego
- San José
- Sendai
- Seongnam-si
- Seoul
- Singapore
- Sremska Kamenica
- St Leonards
- Taichung City
- Tainan City
- Taipei City
- tambon-kho-hong
- Taoyuan City
- Temuco
- Toronto
- Tucson
- Tyler
- Ube
- Vancouver
- Westmead
- Yokohama
- Yonago
NCT05419375 BX43361
Trial Summary
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors
Eligibility Criteria
General Inclusion Criteria:
- Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol
- Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal product, and that the participant has the awareness and willingness to participate in said trial
Inclusion Criteria for Participants with Stage III NSCLC
- Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology based on 8th edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) cancer staging system
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
General Exclusion Criteria:
- History of malignancy other than NSCLC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death
- Any condition that may affect the interpretation of study results
- Significant liver or cardiovascular disease
- Prior allogenic stem-cell or solid-organ transplantation
For the latest version of this information please go to www.forpatients.roche.com